Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature

BACKGROUND: Checkpoint inhibitors (CPIs) have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation (SOT) recipients have been excluded from clinical trials owing to concerns about alloimmunity,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Abdel-Wahab, Noha, Safa, Houssein, Abudayyeh, Ala, Johnson, Daniel H., Trinh, Van Anh, Zobniw, Chrystia M., Lin, Heather, Wong, Michael K., Abdelrahim, Maen, Gaber, A. Osama, Suarez-Almazor, Maria E., Diab, Adi
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2019
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469201/
https://ncbi.nlm.nih.gov/pubmed/30992053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0585-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi